Last updated on December 2019

Efficacy and Safety of 177Lu-edotreotide PRRT in GEP-NET Patients

Brief description of study

The purpose of the study is to evaluate efficacy and safety of Peptide Receptor Radionuclide Therapy (PRRT) with 177Lu-Edotreotide compared to targeted molecular therapy with Everolimus in patients with inoperable, progressive, somatostatin receptor-positive (SSTR+), neuroendocrine tumours of gastroenteric or pancreatic origin (GEP-NET).

Clinical Study Identifier: NCT03049189

Find a site near you

Start Over

Royal North Shore Hospital

Saint Leonards, Australia
  Connect »

Kantonsspital St. Gallen

Saint Gallen, Switzerland
  Connect »

Kings College Hospital

London, United Kingdom
  Connect »